Edgar Filing: Cooper Jeffrey H - Form 4

Cooper Jeffn Form 4 March 04, 2											
FORM	1 4		CECUD				NCEO			PPROVAL	
	UNIII	LDSIAIE		shington,			NGE C	COMMISSION	OMB Number:	3235-0287	
Check th if no lon subject to Section 4 Form 4 of Form 5 obligation may con <i>See</i> Instr 1(b).	ger o 16. or Filed ons tinue.	pursuant to 17(a) of the	DF CHAN Section 1	GES IN I SECUR 6(a) of the ility Hold	BENEF ITIES e Securit ling Con	ICIA ties E	Exchange y Act of	NERSHIP OF e Act of 1934, 1935 or Section	Expires: Estimated a burden hou response		
(Print or Type	Responses)										
Cooper Jeffrey H Symbol BION			Symbol BIOMA	suer Name and Ticker or Trading ol MARIN PHARMACEUTICAL [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				f Earliest Transaction				Director 10% Owner X Officer (give title Other (specify			
C/O BIOM PHARMAG DIGITAL I	CEUTICAL IN	IC., 105	(Month/D 02/29/20	-				below)	below) ef Financial Of		
				endment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)	Tabl	o I Non D	animatina	Same	ition A on	Person	or Donoficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Ye	Date 2A. Dee ear) Executi any	emed	3.	4. Securi	ties A ispose 4 and (A)	cquired d of (D)	5. Amount of	or Beneficially Owned 6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)		
Common Stock	02/29/2008			Code V S	Amount 300	or (D) D	Price \$ 37.82	(Instr. 3 and 4) 6,610	D		
Common Stock	02/29/2008			S	500	D	\$ 37.89	6,110	D		
Common Stock	02/29/2008			S	1,800	D	\$ 37.92	4,310	D		
Common Stock	02/29/2008			S	1,100	D	\$ 37.96	3,210	D		
	02/29/2008			S	800	D		2,410	D		

Edgar Filing: Cooper Jeffrey H - Form 4

Common Stock					\$ 37.97		
Common Stock	02/29/2008	S	300	D	\$ 37.98	2,110	D
Common Stock	02/29/2008	S	600	D	\$ 37.99	1,510	D
Common Stock	02/29/2008	S	405	D	\$ 38	1,105	D
Common Stock	02/29/2008	S	100	D	\$ 38.01	1,005	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
Cooper Jeffrey H C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Chief Financial Officer					

Signatures

/s/ G. Eric Davis, 03/04/2008 Attorney-in-Fact

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.